In Vitro Evaluation of Repurposed Antivirals and Their Combinations Against Respiratory Syncytial Virus and Human Parainfluenza Virus Type 2: Evidence of Ribavirin–Oseltamivir Synergy
Journal of Medical Virology · 2026-11 · 98 (11)
DOI: 10.1002/jmv.71202 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, online erschienen am 28.10.2026. Verfasst von Fatima Nur Olcay und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Istanbul University, Istanbul, Turkiye. Hauptthemen laut MEDLINE: Antiviral Agents, Ribavirin, Drug Synergism, Oseltamivir. Die Arbeit nennt 50 Literaturangaben. Gefördert von: Istanbul University, Istanbul Üniversitesi.
Abstract (Originalsprache)
Treating respiratory viral infections remains challenging, necessitating exploration of novel therapeutic approaches. Alternative strategies, such as drug repurposing or combinations, are essential for treating them. This study evaluated the in vitro activities of the antivirals ribavirin, favipiravir, and oseltamivir, and the mucolytic drugs N‐acetylcysteine (NAC) and erdosteine, alone or in combination, against Human Parainfluenza Virus (HPIV) and Respiratory Syncytial Virus (RSV). HPIV‐2 and RSV were cultured in VERO and HEp‐2 cell lines, respectively. Antiviral efficacy was assessed by calculating IC 50 values using MTT and plaque reduction assays. For combination studies, synergy scores were analyzed using the SynergyFinder program. We investigated potential interactions underlying the synergistic activities using an in silico approach, that combined virtual screening and molecular docking. The IC 50 values of ribavirin, favipiravir, and oseltamivir against HPIV‐2 and RSV ranged from 4.46 to 14.1 µg/mL, and the results from both methods were highly similar. All three antivirals' cytotoxicity was well above their C‐max, and SIs were 12.43‐36.69 for HPIV‐2 and 15.88–38.12 for RSV. The ribavirin‐oseltamivir combination synergy scores of 13.35 for HPIV‐2 and 17.98 for RSV indicate clear synergism, while other combinations were additive. Docking analysis identified potential molecular interactions that may contribute to the antiviral activity of the ribavirin–oseltamivir combination against RSV and HPIV‐2. Ribavirin, favipiravir, and oseltamivir showed good activity against HPIV‐2 and RSV, and the ribavirin‐oseltamivir combination exhibited strong synergistic interactions, suggesting promising therapeutic potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Istanbul University, Istanbul, Turkiye.
- Department of Bioengineering, University of Health Sciences, Istanbul, Turkiye.
ORCID-Profile: Fatima Nur Olcay, Tuba Sevimoglu, Sibel Dosler
Förderung
- Istanbul University
- Istanbul Üniversitesi
Zitieren
APA
Olcay, F. N., Sevimoglu, T., & Dosler, S. (2026). In Vitro Evaluation of Repurposed Antivirals and Their Combinations Against Respiratory Syncytial Virus and Human Parainfluenza Virus Type 2: Evidence of Ribavirin–Oseltamivir Synergy. Journal of Medical Virology, 98(11). https://doi.org/10.1002/jmv.71202
Vancouver
Olcay FN, Sevimoglu T, Dosler S. In Vitro Evaluation of Repurposed Antivirals and Their Combinations Against Respiratory Syncytial Virus and Human Parainfluenza Virus Type 2: Evidence of Ribavirin–Oseltamivir Synergy. Journal of Medical Virology. 2026;98(11). doi:10.1002/jmv.71202
BibTeX
@article{Olcay2026,
author = {Olcay, Fatima Nur and Sevimoglu, Tuba and Dosler, Sibel},
title = {In Vitro Evaluation of Repurposed Antivirals and Their Combinations Against Respiratory Syncytial Virus and Human Parainfluenza Virus Type 2: Evidence of Ribavirin–Oseltamivir Synergy},
journal = {Journal of Medical Virology},
year = {2026},
volume = {98},
number = {11},
doi = {10.1002/jmv.71202}
}
EUVIMED